BioPharma Dive April 30, 2024
The biotech’s CEO, Sergio Duron, said his team will use the funds to bring “several development candidates” towards clinical trials in the next few years.
Enlaza Therapeutics, a San Diego-based startup, has raised a $100 million Series A round to develop biologic cancer drugs designed to latch onto their targets through covalent bonds.
The new funding announced Tuesday and led by the life sciences investment arm of J.P. Morgan comes two years after the company debuted with a $61 million seed round. The cash should pave the way for the company to begin its first clinical trials.
Enlaza develops covalent drugs, known as such because they tightly bind to proteins instead of bouncing in and out of their targets. Such...
Today's Sponsors
Today's Sponsor